This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Age-related Macular Degeneration
+1

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Sponsored by Perceive Biotherapeutics, Inc.

About this trial

Last updated a year ago

Study ID

PBI-AMD-001

Status

Active, not recruiting

Type

Interventional

Phase

Phase 1/Phase 2

Placebo

No

Accepting

18-75 Years
50+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 3 years ago

What is this trial about?

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

What are the participation requirements?

Yes

Inclusion Criteria

1. Are ≥50 years of age at the time of consent.

2. Are willing and able to understand and provide written informed consent.

3. Are willing and able to return for scheduled treatment and follow-up examinations.

4. Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.

5. Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.

6. Absence of signs of non-exudative MNV.

7. Additional Ocular Inclusion Criteria

8. Meet certain genotype criteria for risk of AMD.

No

Exclusion Criteria

1. Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.

2. Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Locations

Location

Status